Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
List view / Grid view
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
Researchers say computational analyses suggest the bradykinin system may explain some of the symptoms of COVID-19, providing a drug target.
Researchers grew large crystals and used an X-ray machine with a less intense beam to elucidate the structure of the SARS-CoV-2 main protease at room temperature.
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
From the world’s flagship neutron science facility, Institut Laue-Langevin (ILL), Matthew Blakeley shares insights into how they are harnessing the power of neutrons to aid their search for new cancer treatments.